Comparison of Clinical, Pathological, and Prognostic Features in Mutant and Wild-Type Male Breast Cancer Patients

Overview

Journal Eur J Breast Health

Publisher Galenos Publishing House

Date 2022 Oct 17

PMID 36248747

Authors

Izzet Dogan

Esra Aydin

Hulya Yazici

Pinar Saip

Affiliations

Soon will be listed here.

Abstract

Objective: Published studies on male breast cancer (MBC) and mutations are scarce and usually include, a small number of patients. The clinicopathological characteristics of mutant and wild-type MBC patients were compared in more than forty patients in this study.

Materials And Methods: A retrospective review of MBC patients' clinical and histopathological data was conducted. To compare the patients' characteristics, chi-square test and Fisher's Exact test were utilized. Kaplan-Meier analysis was used to examine the survival analysis.

Results: In total 43 cases were reviewed. The average duration of follow-up was 35.8 months. mutations were found in 11 (25.6%) of the patients. mutations were found in four patients (9.3%), mutations in six patients (14%), and and mutations in one patient (2.3%). The median age at diagnosis was 58 years old, and there was no statistically significant difference between groups ( = 0.7). Tumor location ( = 0.3), human epidermal growth factor receptor 2 overexpression ( = 0.5), estrogen receptor status ( = 0.05), progesterone receptor status ( = 0.6), tumor stage ( = 0.9), lymph node positivity ( = 0.5), tumor histology ( = 0.06), and recurrence status ( = 0.6) were similar between -wild type and -mutated patients. Overall survival averaged 115.6 months (range: 76.0-155.3), with no statistically significant differences between groups ( = 0.6).

Conclusion: This study investigated clinical and pathological characteristics and prognoses of wild and mutant-type MBC and these were similar in all groups studied.

References

Forsti A, Luo L, Vorechovsky I, Soderberg M, Lichtenstein P, Hemminki K . Allelic imbalance on chromosomes 13 and 17 and mutation analysis of BRCA1 and BRCA2 genes in monozygotic twins concordant for breast cancer. Carcinogenesis. 2001; 22(1):27-33. DOI: 10.1093/carcin/22.1.27. View

Tai Y, Domchek S, Parmigiani G, Chen S . Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007; 99(23):1811-4. PMC: 2267289. DOI: 10.1093/jnci/djm203. View

Gudmundsdottir K, Ashworth A . The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006; 25(43):5864-74. DOI: 10.1038/sj.onc.1209874. View

Baretta Z, Mocellin S, Goldin E, Olopade O, Huo D . Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore). 2016; 95(40):e4975. PMC: 5059054. DOI: 10.1097/MD.0000000000004975. View

Gucalp A, Traina T, Eisner J, Parker J, Selitsky S, Park B . Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. 2018; 173(1):37-48. PMC: 7513797. DOI: 10.1007/s10549-018-4921-9. View

Silvestri V, Barrowdale D, Mulligan A, Neuhausen S, Fox S, Karlan B . Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016; 18(1):15. PMC: 4746828. DOI: 10.1186/s13058-016-0671-y. View

Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, Forestieri V . Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. BMC Cancer. 2016; 16:375. PMC: 4932666. DOI: 10.1186/s12885-016-2414-y. View

Zhong Q, Peng H, Zhao X, Zhang L, Hwang W . Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. 2014; 21(1):211-20. PMC: 4286460. DOI: 10.1158/1078-0432.CCR-14-1816. View

Chavez-MacGregor M, Clarke C, Lichtensztajn D, Hortobagyi G, Giordano S . Male breast cancer according to tumor subtype and race: a population-based study. Cancer. 2013; 119(9):1611-7. PMC: 3971835. DOI: 10.1002/cncr.27905. View

10.

Liu N, Johnson K, Ma C . Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis. Clin Breast Cancer. 2018; 18(5):e997-e1002. DOI: 10.1016/j.clbc.2018.06.013. View

11.

Atchley D, Albarracin C, Lopez A, Valero V, Amos C, Gonzalez-Angulo A . Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008; 26(26):4282-8. PMC: 6366335. DOI: 10.1200/JCO.2008.16.6231. View

12.

Ottini L, Silvestri V, Rizzolo P, Falchetti M, Zanna I, Saieva C . Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Res Treat. 2012; 134(1):411-8. DOI: 10.1007/s10549-012-2062-0. View

13.

Gomez-Raposo C, Tevar F, Moyano M, Lopez Gomez M, Casado E . Male breast cancer. Cancer Treat Rev. 2010; 36(6):451-7. DOI: 10.1016/j.ctrv.2010.02.002. View

14.

Yalaza M, Inan A, Bozer M . Male Breast Cancer. J Breast Health. 2017; 12(1):1-8. PMC: 5351429. DOI: 10.5152/tjbh.2015.2711. View

15.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

16.

Cardoso F, Bartlett J, Slaets L, van Deurzen C, van Leeuwen-Stok E, Porter P . Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2017; 29(2):405-417. PMC: 5834077. DOI: 10.1093/annonc/mdx651. View

17.

Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S . Association Between Status and Triple-Negative Breast Cancer: A Meta-Analysis. Front Pharmacol. 2018; 9:909. PMC: 6111442. DOI: 10.3389/fphar.2018.00909. View